Histogen (HSTO) Competitors $0.03 0.00 (0.00%) As of 03/24/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrendsBuy This Stock HSTO vs. SRNE, TFFP, UPC, HEPA, SMFL, SCPS, VAXX, NAVB, EVLO, and CMRAShould you be buying Histogen stock or one of its competitors? The main competitors of Histogen include Sorrento Therapeutics (SRNE), TFF Pharmaceuticals (TFFP), Universe Pharmaceuticals (UPC), Hepion Pharmaceuticals (HEPA), Smart for Life (SMFL), Scopus BioPharma (SCPS), Vaxxinity (VAXX), Navidea Biopharmaceuticals (NAVB), Evelo Biosciences (EVLO), and Comera Life Sciences (CMRA). These companies are all part of the "pharmaceutical products" industry. Histogen vs. Sorrento Therapeutics TFF Pharmaceuticals Universe Pharmaceuticals Hepion Pharmaceuticals Smart for Life Scopus BioPharma Vaxxinity Navidea Biopharmaceuticals Evelo Biosciences Comera Life Sciences Sorrento Therapeutics (NASDAQ:SRNE) and Histogen (NASDAQ:HSTO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk. Is SRNE or HSTO more profitable? Company Net Margins Return on Equity Return on Assets Sorrento TherapeuticsN/A N/A N/A Histogen N/A N/A N/A Which has more volatility and risk, SRNE or HSTO? Sorrento Therapeutics has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500. Comparatively, Histogen has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Do institutionals and insiders hold more shares of SRNE or HSTO? 0.0% of Sorrento Therapeutics shares are owned by institutional investors. 2.6% of Sorrento Therapeutics shares are owned by company insiders. Comparatively, 3.3% of Histogen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has better valuation & earnings, SRNE or HSTO? Histogen has lower revenue, but higher earnings than Sorrento Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSorrento Therapeutics$60.32M0.01-$572.84MN/AN/AHistogen$19K6.98-$10.62M-$2.81-0.01 Does the MarketBeat Community believe in SRNE or HSTO? Sorrento Therapeutics received 603 more outperform votes than Histogen when rated by MarketBeat users. Likewise, 67.85% of users gave Sorrento Therapeutics an outperform vote while only 58.33% of users gave Histogen an outperform vote. CompanyUnderperformOutperformSorrento TherapeuticsOutperform Votes61067.85% Underperform Votes28932.15% HistogenOutperform Votes758.33% Underperform Votes541.67% Does the media prefer SRNE or HSTO? In the previous week, Sorrento Therapeutics had 1 more articles in the media than Histogen. MarketBeat recorded 1 mentions for Sorrento Therapeutics and 0 mentions for Histogen. Sorrento Therapeutics' average media sentiment score of 0.00 equaled Histogen'saverage media sentiment score. Company Overall Sentiment Sorrento Therapeutics Neutral Histogen Neutral SummarySorrento Therapeutics beats Histogen on 6 of the 9 factors compared between the two stocks. Remove Ads Get Histogen News Delivered to You Automatically Sign up to receive the latest news and ratings for HSTO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HSTO vs. The Competition Export to ExcelMetricHistogenPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$133,000.00$6.99B$5.68B$8.32BDividend YieldN/A2.72%4.55%4.02%P/E Ratio-0.017.2324.5519.25Price / Sales6.98230.77395.7394.10Price / CashN/A65.6738.1634.64Price / Book0.016.617.064.46Net Income-$10.62M$142.13M$3.19B$247.07M7 Day PerformanceN/A2.79%1.49%3.06%1 Month PerformanceN/A2.70%5.87%-2.85%1 Year PerformanceN/A-4.42%14.94%4.64% Histogen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HSTOHistogenN/A$0.03flatN/A-90.4%$133,000.00$19,000.00-0.0120SRNESorrento TherapeuticsN/A$0.00flatN/A-91.3%$386,000.00$60.32M0.00800Analyst ForecastNews CoverageTFFPTFF PharmaceuticalsN/A$0.07flat$44.00+67,592.3%N/A$289,000.00$-70,983.00-0.0119Upcoming EarningsUPCUniverse PharmaceuticalsN/A$0.10-4.8%N/A-85.2%$168,000.00$26.73M0.00220Positive NewsGap DownHEPAHepion Pharmaceuticals0.2951 of 5 stars$0.02-9.6%N/A-99.4%$145,000.00N/A0.0020Gap DownHigh Trading VolumeSMFLSmart for LifeN/A$0.01flatN/A-99.9%$47,000.00$11.11M0.00110Gap DownSCPSScopus BioPharmaN/A$0.00flatN/A-87.0%$13,000.00N/A0.009VAXXVaxxinityN/A$0.00-99.8%N/A-99.3%$13,000.00N/A0.0090Gap DownNAVBNavidea BiopharmaceuticalsN/A$0.00-50.0%N/A-99.3%$10,000.00$8,126.000.0010Analyst ForecastNews CoverageGap DownEVLOEvelo BiosciencesN/A$0.00flatN/A-99.2%$9,000.00N/A0.00120Upcoming EarningsCMRAComera Life SciencesN/A$0.00flatN/AN/A$6,000.00$1.00M0.002 Remove Ads Related Companies and Tools Related Companies Sorrento Therapeutics Competitors TFF Pharmaceuticals Competitors Universe Pharmaceuticals Competitors Hepion Pharmaceuticals Competitors Smart for Life Competitors Scopus BioPharma Competitors Vaxxinity Competitors Navidea Biopharmaceuticals Competitors Evelo Biosciences Competitors Comera Life Sciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HSTO) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Histogen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Histogen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
